TY - JOUR T1 - FVC变异例特发性肺纤维化和6分钟步行试验的作用，以进一步预测变化JF - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.02151-2019 VL - 55 - 5 SP -1902151 AU - 弥敦道，史蒂芬D. AU - 杨，明AU - Morgenthien，伊丽莎白A. AU - 斯托弗，约翰·Y1 - 2020年5月1日UR - //www.qdcxjkg.com/content/55/5 / 1902151.abstract N2 - 特发性肺纤维化（IPF）的疾病进展是通过在用力肺活量（FVC）[1]下降监测。在％的绝对或相对下降预测FVC≥10％的与死亡率相关[2，3]。的FVC下降的措施被选定为主要终点中的枢转相抗纤维化治疗[4-6]的3个试验。尽管在IPF人口FVC下降变化趋势基本一致，疾病进展的个人率是不可预测的，充满变数：在FVC显著变化随时间观察，和之前的下降是未来的一个贫穷的预测FVC下降[1，7，8]。In new trials in IPF, the margin for reducing FVC decline is smaller (∼70 mL) in patients who are receiving an investigational drug with background antifibrotics than in the placebo arms of past trials (130–210 mL) [9].Variability in 3-month changes in FVC was examined in 954 patients with IPF (n=3966 observations) from phase 3 trials; concurrent 3-month decline in the FVC and 6MWD (n=1321 observations) predicted further decline in FVC over the subsequent 3 months http://bit.ly/2GfBKW3We thank the patients who participated in the studies and their families. Support for third-party writing assistance, furnished by Benjamin Ricca of Health Interactions, Inc., was provided by F. Hoffmann-La Roche Ltd. ER -